A Proof of Concept Study Non-Randomized, Single-Center Pilot Trial Assessing The Safety/Efficacy Of Dual Targeting Of Peripheral And Central Humoral Alloimmune Memory With Anti-CD38 (Daratumumab) And Costimulation Blockade With CTLA4-Ig (Belatacept) In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation

2024-518128-66-00 Protocol 38RC21.171 COMBAT Human pharmacology (Phase I) - Other Ended

Start 11 Jan 2022 · End 22 Apr 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 38RC21.171 COMBAT

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 15
Countries 1
Sites 1

patients with cPRA or TGI ≥ 95% on the deceased donor kidney transplant waiting list, who have not received a compatible donor offer for ≥1 year.

Key facts

Sponsor
Centre Hospitalier Universitaire Grenoble Alpes
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutics [E02]
Trial duration
11 Jan 2022 → 22 Apr 2025
Decision date (initial)
2024-11-08
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-518128-66-00
EudraCT number
2021-002306-27
ClinicalTrials.gov
NCT05145296

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

patients with cPRA or TGI ≥ 95% on the deceased donor kidney transplant waiting list, who have not received a compatible donor offer for ≥1 year.

VersionLevelCodeTermSystem organ class
22.0 LLT 10023418 Kidney failure 10038359

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire Grenoble Alpes

Sponsor organisation
Centre Hospitalier Universitaire Grenoble Alpes
Address
Boulevard De La Chantourne, Cs 10217, La Tronche Cs 10217 La Tronche
City
Grenoble Cedex 9
Postcode
38043
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire Grenoble Alpes
Contact name
Malvezzi

Public contact point

Organisation
Centre Hospitalier Universitaire Grenoble Alpes
Contact name
Malvezzi

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 15 1
Rest of world 0

Investigational sites

France

1 site · Ended
Centre Hospitalier Universitaire Grenoble Alpes
Nephrology, Boulevard De La Chantourne, Cs 10217, Grenoble Cedex 9

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2022-01-11 2022-01-19 2024-04-29

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-03 France Acceptable
2024-11-08
2024-11-08